Daraxonrasib improved survival in metastatic pancreatic cancer in Phase III, signaling meaningful progress for therapies targeting RAS‑driven disease.

Co-primary efficacy in RAS G12–mutant PDAC included statistically significant OS and PFS gains assessed by blinded ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival -- Company intends to include these data in a future New Drug Application submission to the ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, ...

The firm said its pan-RAS inhibitor daraxonrasib demonstrated a statistically significant improvement in survival outcomes in a registrational trial, regardless of RAS mutation status.

The attack on Qatar’s Ras Laffan complex exposed deep structural vulnerabilities, shifting expectations from oversupply to prolonged tightness and volatility. Lost Qatari volumes cannot easily be ...

⁠India is a big importer of LPG and LNG and relies heavily on supplies from Middle Eastern countries such as Qatar. (AI image) Middle East conflict impact: What happens when the world's largest ...

Qatar’s state oil giant QatarEnergy said on Wednesday (March 18, 2026) that “extensive damage” has been caused ‌after the Ras Laffan Industrial City was subjected to missile attacks, shortly ⁠after ...

Qatar's state-run energy company, QatarEnergy, said on Wednesday that fires caused by Iranian strikes on its main gas facility had resulted in “extensive damage,” following Tehran’s warning of ...